Now showing items 11-20 of 21
VM-26 in colorectal carcinoma: A Southwest Oncology Group study
(Kluwer Academic Publishers; Springer Science+Business Media, 1990-02)
In this multi-institutional phase II study, VM-26 or Teniposide was administered to forty-two patients with advanced colorectal cancer. Patients were initially treated at 60 mg/M 2 daily for 5 days with dose adjustments ...
Comparison of the adrenalytic activity of mitotane and a methylated homolog on normal adrenal cortex and adrenal cortical carcinoma
(Springer-Verlag, 1993-11)
Mitotane is an important adrenalytic drug for the treatment of adrenal cancer whose use is limited by toxicity. Reports from another laboratory indicated that a methylated homolog of Mitotane (Mitometh) tested in guinea ...
Phase II evaluation of mitoxantrone in advanced pancreatic carcinoma: A Southwest Oncology Group study
(Kluwer Academic Publishers; Springer Science+Business Media, 1990-02)
Patient with advanced adenocarcinoma of the pancreas and no prior chemotherapy were treated on a Phase II trial of mitoxantrone. Doses were adjusted for hepatic dysfunction as defined by bilirubin. Twenty-four patients ...
Multicenter phase II study of brequinar sodium in patients with advanced gastrointestinal cancer
(Kluwer Academic Publishers; Springer Science+Business Media, 1993-02)
Eighty-six patients with advanced colorectal, gastric or pancreatic carcinoma and no prior exposure to chemotherapy were treated with brequinar sodium. Brequinar was administered at a median weekly dose of 1200 mg/m 2 ...
Multicenter phase II study of brequinar sodium in patients with advanced lung cancer
(Springer-Verlag, 1993-01)
A total of 53 patients with advanced lung cancer [non-small-cell (NSC), 21; small-cell (SC), 32] were treated with brequinar sodium. All of the NSC patients were chemotherapy-naive, but 31/32 (97%) SC patients had failed ...
Multicenter phase II trial of brequinar sodium in patients with advanced squamous-cell carcinoma of the head and neck
(Springer-Verlag, 1992-03)
A total of 19 patients with advanced squamous-cell carcinoma of the head and neck who had not previously been exposed to chemotherapy were treated with brequinar sodium as first-line chemotherapy. Brequinar was given ...
Phase II evaluation of piroxantrone in renal cell carcinoma
(Kluwer Academic Publishers; Springer Science+Business Media, 1992-06)
The Southwest Oncology Group (SWOG) studied the response rate and toxicity of piroxantrone (150 mg/m 2 q 21 days) in patients with advanced metastatic renal cell carcinoma. Among 32 eligible patients, there were no partial ...
The role of deoxycytidine-metabolizing enzymes in the cytotoxicity induced by 3′-amino-2′,3′-dideoxycytidine and cytosine arabinoside
(Springer-Verlag, 1992-03)
The cellular metabolism of 3′-amino-2′,3′-dideoxycytidine (3′-NH 2 -dCyd), a cytotoxic agent previously reported to be a poor substrate for purified Cyd/dCyd deaminase (dCydD), was compared with that of cytosine arabinoside ...
Phase II Trial of Suramin in Patients with Metastatic Renal Cell Carcinoma
(Kluwer Academic Publishers; Springer Science+Business Media, 1999-05)
This study was conducted to assess the efficacy and toxicity of suramin administered using a fixed dose schedule in patients with advanced renal cell carcinoma. Fourteen eligible patients with advanced renal cell carcinoma ...
Inhibition of fludarabine metabolism by arabinosylcytosine during therapy
(Springer-Verlag, 1992-05)
The active 5′-triphosphate of arabinosyl-2-fluoroadenine (F-ara-ATP) increases the anabolism of arabinosylcytosine (ara-C), whereas ara-C 5′-triphosphate inhibits the phosphorylation of arabinosyl-2-fluoroadenine (F-ara-A) ...